Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 31.88% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 31.88% YoY), while the FY2025 annual figure was $1.3 billion, up 25.12% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.3 billion, down from $1.3 billion in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $1.3 billion in Q4 2025, with the low at $115.7 million in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $876.8 million (2024), against an average of $815.6 million.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities rose 6.66% in 2022, then surged 651.34% in 2023.
• Vertex Pharmaceuticals' Other Non-Current Liabilities stood at $685.8 million in 2022, then climbed by 27.98% to $877.7 million in 2023, then climbed by 15.6% to $1.0 billion in 2024, then advanced by 25.12% to $1.3 billion in 2025, then fell by 1.11% to $1.3 billion in 2026.
• Business Quant data shows VRTX's Other Non-Current Liabilities at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.